Although antineoplastics have retained position as a protected class of medicines with open formularies, CMS did agree to implement Step Therapy with Medicare B medications.  And despite receiving over 4000 comments regarding price concessions and DIR fees, the agency has decided to not include a proposal to pass on price concessions negotiated by the pharmacy to patients in 2020.  These actions may limit patient access to medications and fail to address the high costs they often pay at the pharmacy counter.  Read more